RAF1 and neoplasm: For the latter, SHP2 has become a potential and attractive target, especially with the aim of interfering with tumor intrinsic RAS-RAF-MEK-ERK-pathway hyperactivation, even as a combination partner for the novel groundbreaking class of mutant-specific RAS-inhibitors (9).